Table 3.
The effect of clinicopathologic factor and UNC13C expression on mortality density and adjusted hazard ratio (aHR) among OSCC patients
| Factors | No. of patients | Follow-up | No. of death | Mortality densitya | aHRb | (95% CI) | Interaction |
|---|---|---|---|---|---|---|---|
| (person-year) | P-value | ||||||
| Overall mortality from primary malignancy to death | |||||||
| T classification | |||||||
| I/II | 83 | 554.9 | 22 | 4.0 | 1 | ||
| III/IV | 50 | 242 | 26 | 10.7 | 1.9 | (1.4–2.8) | 0.0002 |
| N classification | |||||||
| N0/N1 | 112 | 736.4 | 33 | 4.5 | 1 | ||
| N2/N3 | 21 | 60.5 | 15 | 24.8 | 2.9 | (2.0–4.1) | <0.0001 |
| AJCC tumor stage | |||||||
| I/II | 68 | 483.1 | 16 | 3.3 | 1 | ||
| III/IV | 65 | 313.7 | 32 | 10.2 | 2.5 | (1.7–3.7) | <0.0001 |
| Tumor differentiation | |||||||
| Well | 21 | 160.1 | 0 | 0.0 | 1 | ||
| Moderate/poor | 112 | 636.7 | 48 | 7.5 | 2.9 | (1.4–5.6) | 0.0025 |
| c-MYC expression | |||||||
| High | 75 | 455.7 | 23 | 5.0 | 1 | ||
| Low | 58 | 341.2 | 25 | 7.3 | 1.4 | (0.82–2.53) | 0.21 |
| Combined effect | |||||||
| T stage/c-MYCc | |||||||
| I/II/High | 52 | 352.5 | 12 | 3.4 | 1 | 0.0233 | |
| I/II/Low | 31 | 202.4 | 10 | 4.9 | 1.4 | (0.6–3.3) | |
| III/IV/High | 23 | 138.8 | 15 | 10.8 | 2.6 | (1.1–5.8) | |
| III/IV/Low | 27 | 103.2 | 11 | 10.7 | 2.9 | (1.4–6.2) | |
| AJCC tumor stage/c-MYCd | |||||||
| I/II/High | 43 | 313.6 | 8 | 2.6 | 1 | 0.0017 | |
| I/II/Low | 25 | 169.45 | 8 | 4.7 | 1.8 | 0.7–4.7 | |
| III/IV/High | 32 | 171.7 | 15 | 8.7 | 3.4 | 1.4–7.7 | |
| III/IV/Low | 33 | 142 | 17 | 12.0 | 6.2 | 1.5–7.8 | |
Note: aMortaility density was displayed as per 100 people-years. baHR was adjusted for gender and age. cSignificant multiplicative-scale interaction between T stage and low expression on mortality risk was identified (P for interaction, 0.0233). dSignificant multiplicative-scale interaction between AJCC stage and low expression on mortality risk was identified (P for interaction, 0.0017).
Abbreviation: AJCC, American Joint Committee on Cancer